• MM-141 Trial Does Not Meet Primary, Secondary Endpoints americanpharmaceuticalreview
    June 27, 2018
    Merrimack announced top-line results from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer and high serum levels o
PharmaSources Customer Service